Assessment of consistency of treatment effects in multiregional clinical trials

Drug Information Journal

Volumn 44, Issue 5, 2010, Pages 617-632

  Quan, Hui ^a   Li, Mingyu ^b   Chen, Joshua ^c   Gallo, Paul ^d   Binkowitz, Bruce ^c   Ibia, Ekopimo ^c   Tanaka, Yoko ^e   Ouyang, Soo Peter ^b   Luo, Xiaolong ^b   Li, Gang ^f   Menjoge, Shailendra ^g   Talerico, Steven ^c   Ikeda, Kimitoshi ^d  

^a SANOFI   (France)

^b Celgene   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Novartis Environ Fate and Effects   (United States)

^e ELI LILLY   (United States)

^f JOHNSON AND JOHNSON   (United States)

^g Boehringer Ingelheim   (United States)

Author keywords

Ethnic effect; Interaction; Noninferiority; Power; Random effect model; Sample size

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL TRIAL; MULTIREGIONAL CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RANDOM SAMPLE; RESEARCH PRIORITY; REVIEW; SIMULATION; STUDY DESIGN; SURVIVAL; THERAPY EFFECT;

EID: 78650217349     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400509     Document Type: Review

References (14)

1. ICH. International Conference on Harmonization Tripartite Guidance E5. Ethnic factor in the acceptability of foreign data. Federal Register, 1998;83:31790-31796.
2. Shih WJ. Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. Control Clin Trials. 2001;22:357-366.
3. Chow SC, Shao J, Hu OYP. Assessing sensitivity and similarity in bridging studies. J Biopharm Stat. 2002;12:385-400. (Pubitemid 35332823)
4. Liu JP, Chow SC. Bridging studies in clinical development. J Biopharm Stat. 2002;12:359-367.
5. Hsiao CF, Xu JZ, Liu JP. A group sequential approach to evaluation of bridging studies. J Biopharm Stat. 2003;13:793-801. (Pubitemid 37259718)
6. Ministry of Health, Labour and Welfare of Japan. Basic concepts for joint international clinical trials. September 28, 2007.
7. European Medicines Agency. Reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU-population (draft). EMEA Doc. Ref. CHMP/EWP/692702/2008. February 2009. http://www.emea.europa.eu/pdfs/human/ewp/69270208en.pdf.
8. Quan H, Zhao PL, Zhang J, Roessner M, Aizawa K. Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance. Pharm Stat. 2009; early view, http://www3.interscience.wiley.com/cgi- bin/fulltext/122432408/PDFSTART.
9. Kawai N, Chuang-Stein C, Komiyama O, Li Y. An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Inf J. 2007;42:139-147.
10. Quan H, Li M, Chen J, et al. Assessment of consistency of treatment effects in multi-regional clinical trials. Sanofi-Aventis Tech Report #034, September 2009.
11. Hung HMJ. Design considerations for bridging clinical trials and global clinical trials. Presented at DIA Annual Meeting, Atlanta, GA, June 20, 2007.
12. Schoenfeld D. The asymptotic properties of non-parametric tests for comparing survival distributions. Biometrika. 1981;68:316-319.
13. Pan G, Wolfe DA. Test for qualitative interaction of clinical significance. Stat Med. 1997;16:1645-1652. (Pubitemid 27341619)
14. Gail M, Simon R. Testing for qualitative interaction between treatment effects and patient subsets. Biometrics. 1985;41:361-372.